Last reviewed · How we verify

melatonin in children premedication

Azienda Ospedaliera Universitaria Policlinico "G. Martino" · FDA-approved active Small molecule

Melatonin binds to melatonin receptors (MT1 and MT2) in the brain to promote sleep and reduce anxiety in pediatric patients before medical procedures.

Melatonin binds to melatonin receptors (MT1 and MT2) in the brain to promote sleep and reduce anxiety in pediatric patients before medical procedures. Used for Premedication and anxiolysis in children undergoing anesthesia or medical procedures.

At a glance

Generic namemelatonin in children premedication
SponsorAzienda Ospedaliera Universitaria Policlinico "G. Martino"
Drug classMelatonin receptor agonist
TargetMT1 and MT2 melatonin receptors
ModalitySmall molecule
Therapeutic areaAnesthesia/Perioperative Medicine
PhaseFDA-approved

Mechanism of action

Melatonin is an endogenous hormone that regulates circadian rhythm and sleep-wake cycles by activating melatonin receptors in the suprachiasmatic nucleus and other brain regions. In the premedication context, it reduces anxiety and promotes sedation in children undergoing anesthesia or medical procedures, offering a non-pharmacological alternative to benzodiazepines with a favorable safety profile.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: